Kornimate/medical-research-clean huggingface dataset:
review of complex recurrent hernia repair

Conditions: Recurrent Hernia

Summary: abdominal wall incisional hernia is a common finding in patients who have undergone previous intra-abdominal surgeries. common methods of abdominal fascial closure include primary closure, mesh inlay versus onlay, with or without component separation. all these methods have been shown to have recurrence rates for hernia between 3%-60% in the literature. the study describes the investigators innovative and preferred method for reconstruction of the abdominal wall as bars (bony anchoring reinforcement system). this method manages the abdominal fascial integrity to reduce the recurrence of incisional hernia while providing an aesthetically superior abdominal wall contour.

• overview of research * 100 anticipated subjects * data collection methods- patients will be evaluated with serial history and physical exams, as well as emg evaluations. patients will be asked to report their degree of function and satisfaction. * data analysis methods -data that we will collect from patients will serve as anecdotal evidence to support the research theory. * we will collect data from patients from testings conducted at the hospital and private office. we will be conducting pre-testing, post-testing, compare results, and surveys. * the anticipated significance of this research study is that this procedure may greatly improve the quality of life of these severely debilitated patients, reduce the morbidity and mortality rates, and reduce the health care cost burden of chronic care and recurrent hospitalizations. * the bars technique for incisional hernia reconstruction provides excellent reinforcement with improved contour, decreased recurrence rates and decreased morbidity for the abdominal wall.

Eligibility criteria:
inclusion criteria: 1. patients with recurrent abdominal wall incisional hernias 2. age \> 18 3. no medical contraindications to immunosuppressive therapy (in cases utilizing allograft) 4. ability and motivation to follow up appropriately 5. ability and motivation to adhere to rehabilitation regimen 6. stable sequelae of initial cns insult exclusion criteria: minors 1. pregnancy 2. major medical or psychiatric illness, which in the investigator's opinion would prevent completion of treatment and interfere with follow-up. 3. patient unable to tolerate surgery, rehabilitation, or immunosuppressive therapy.

Keywords: bars bony anchoring reinforcement system hernia incisional recurrent abdominal wall reconstruction abdominal wall defect mesh component separation
a multicenter study to evaluate the cios spin and the ion endoluminal system for pulmonary nodule biopsy

Conditions: Lung Cancer

Summary: the overall objective of this study is to evaluate procedure characteristics of pulmonary nodule biopsies using the integrated version of cios spin and the ion endoluminal system.

this study is a post-market, prospective, multicenter, single-arm study of subjects undergoing a pulmonary nodule biopsy using the ion endoluminal system in conjunction with the cios spin. the aim of the study is to evaluate the integrated version of the two systems. the primary outcomes of the study are focused on evaluating the procedure characteristics of the pulmonary nodule biopsy procedure, including diagnostic yield, sensitivity for malignancy, and rate of tool in nodule.

Eligibility criteria:
inclusion criteria: * subject is 18 years or older at the time of the procedure. * pulmonary nodule biopsy attempted/performed using the ion endoluminal system and cios spin 3d imaging. * pulmonary nodule ≤2 cm in largest diameter. * subject able to understand and adhere to study requirements and provide informed consent. exclusion criteria: * planned lymph node staging performed before nodule biopsy. * nodule is a pure ground glass opacity. * plan to biopsy multiple nodules.
eating disorders clinical research network

Conditions: Eating Disorders

Summary: uk eating disorder services are facing unprecedented demand, with effective service delivery hampered by inadequate resources, fragmented services and variable care pathways. individuals with eating disorders, families and clinicians all agree on the critical need to improve care pathways and treatment, leading to better outcomes. eating disorders are serious, complex conditions influenced by a blend of biological, psychological, and environmental factors. the approach of this project is grounded in the "biopsychosocial" model. recently, anorexia research confirms a genetic component, with biological, metabolic, and psychological mechanisms at play. further biological research across eating disorders could allow a better understanding of the mechanisms underlying eating disorder development and better, more personalised treatments. this project will test the feasibility of establishing a uk-wide nhs research network spanning child and adult eating disorder services to enable a step change in the ability to conduct eating disorder research. it will help address fragmentation and facilitate novel biological, psychological, and social research collaborations. the data the investigators gather will be open to all researchers for data analyses, and the collaborations established will form a collaborative network to enable future clinical trials, experimental medicine and psychology. the study will be conducted at child and adult eating disorder services who opt to join the network. participants will be patients receiving treatment for an eating disorder at one of the participating services, and their parents/guardians if applicable. participants will complete questionnaires and have blood and other physical tests as specified in the edcrn dataset. the study will last until 29th october 2026 (the end of the current funding period) and/or when a participant is discharged from treatment, whichever is sooner. for participants discharged before the study ends, there will be an opportunity for patients to complete optional follow-up questionnaires on a periodic basis.


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with an eating disorder under at least 1 of the criteria specified in the dsm-5 and/or icd-9, 10 or 11. * patients who are receiving treatment as inpatients, day-patients or outpatients at a camhs or adult service who is participating in the edcrn. * patients who are receiving treatment in the uk. or: * parents/guardians of patients who have been diagnosed with an eating disorder under at least 1 of the criteria specified in the dsm-5 and/or icd-9, 10 or 11. * parents/guardians of patients who are receiving treatment as inpatients, day-patients or outpatients at a camhs or adult service who is participating in the edcrn. * parents/guardians of patients who are receiving treatment in the uk. exclusion criteria: * individuals who do not meet the criteria specified above will be considered ineligible to participate in the edcrn.
evaluation of frailty in patients with fibrosing interstitial lung diseases: prognostic and therapeutic impact

Conditions: Sarcopenia

Summary: fibrosing interstitial lung diseases (ilds), with idiopathic pulmonary fibrosis being the most common form, primarily affect older individuals and have a poor prognosis, with a median survival of 3 to 5 years. while antifibrotic treatments such as nintedanib and pirfenidone can slow disease progression, their efficacy is often limited by side effects, particularly in elderly patients. a comprehensive patient assessment, including evaluations of frailty and sarcopenia, could optimize care by identifying those at risk for poor outcomes or poor treatment tolerance. frailty, characterized by reduced physiological reserves, and sarcopenia, defined as a loss of muscle mass and strength, are both associated with increased mortality and morbidity risks. although their individual impacts on fibrosing ilds have been documented, the combined effect of these two syndromes on patient prognosis remains unexplored, highlighting the need for further studies to guide therapeutic decision-making.

frailty and sarcopenia are two distinct entities, each capable of worsening patient mortality and morbidity. their association has been studied in the general population in a cohort of over 2,000 individuals aged 70 to 85 years (34816568). the prevalence of sarcopenia among frail participants was 40%. the characteristics and risks faced by patients who were both frail and sarcopenic differed from those who were only sarcopenic or only frail. no study has evaluated the prognostic impact of the combined presence of sarcopenia and frailty on the outcomes of patients with fibrosing ilds.

Eligibility criteria:
inclusion criteria: * patient with fibrosing ild according to the ats/ers/jrs/alat 2022 criteria. * patient aged ≥ 65 years. * outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay). * french-speaking patient. * patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research. exclusion criteria: * patient under legal guardianship, curatorship, or judicial protection. * cognitive disorders limiting the use of questionnaires. * patient with a ct scan showing an early usual interstitial pneumonia (uip) pattern according to the ats/ers/jrs/alat 2022 classification.

Keywords: fibrosing interstitial lung diseases; frailty sarcopenia
postoperative pain in photodynamic therapy using curcumin as a photosensitizer

Conditions: Periapical Diseases; Postoperative Dental Pain; Irrigation Solution; Photodynamic Therapy (PDT)

Summary: in endodontics, various irrigation solutions are used to achieve antibacterial efficacy within the root canal. the antibacterial effect of curcumin-containing root canal solutions, when combined with photodynamic therapy, has been demonstrated in several studies. however, no research has specifically examined their effect on postoperative pain. the aim of this study is to investigate the impact of using a curcumin solution in combination with photodynamic therapy as the final irrigation solution on postoperative pain.

fifty patients were randomly assigned to two groups using a web-based program, according to the selected final irrigation procedure: curcumin-photodynamic therapy or a control group (routine root canal final irrigation with naocl and edta). the teeth will be isolated with a rubber dam, and access cavities will be created. after root canal preparation, the final irrigation procedure will be performed. root canal treatments will then be completed, and the patients' postoperative pain levels will be recorded using follow-up forms.

Eligibility criteria:
inclusion criteria: * healthy patients with aged between 18-60. * incisor, canine, and premolar teeth that had previously undergone root canal treatment * incisor, canine, and premolar teeth with a diagnosis of chronic apical abscess or asymptomatic apical periodontitis * teeth with only 1 root canal * the patients had not used any antibiotics for 3 months before treatment exclusion criteria: * the presence of a root fracture * teeth with any swelling * ankyloses, * periodontal pockets deeper than 4 mm. * teeth which a rubber dam could not be performed * patients with allergy to ibuprofen or ciprofloxacin were also excluded.

Keywords: postoperative pain endodontics root canal irrigation curcumin photodynamic therapy
a study of pf-00547659 in patients with moderate to severe ulcerative colitis

Conditions: Ulcerative Colitis

Summary: to determine the dose or doses of pf-00547659 that will be the most effective to improve or halt the disease symptoms in patients with moderate to severe ulcerative colitis.


Eligibility criteria:
inclusion criteria: * subjects with diagnosis of ulcerative colitis for 3 or more months. * ulcerative colitis must be active beyond the rectum. * must active ulcerative colitis with a total mayo score of 6 to 12 points exclusion criteria: * pregnant or breast feeding. * diagnosis of indeterminate colitis or crohn's disease * subjects with history of colonic or small bowel obstruction or resection.
electro-acupuncture for menopausal transition symptoms

Conditions: Menopause

Summary: this trial aimed at exploring the efficacy as well as safety of electro-acupuncture for mt symptoms.

this was a rct pilot study to assess the efficacy of electro-acupuncture for menopausal transition participants.90 patients were randomly assigned to electro-acupuncture or sham electro-acupuncture group with a ratio of 1:1.during the whole process,all participants, evaluators and statisticians apart from acupuncturists remained strictly blinded.the changes of average 24 h hot flash scores of week8 from baseline was set as primary outcome. with statistical power of 90%, and a two-sided α at 0.05, as well as a drop-out rate less than 20%, sample size was estimated at 90 participants. data analysis was based on itt principles, and 89 participants were included in data analysis(1 participant didn't want to participate).according to methods of locf, missing data were imputed to fill any gaps according to the last visit. for comparison between baseline and treatment (average 24h hot flash scores, mrs, hormone levels), data was tested by the t test or nonparametric test; for comparison between two independent samples, data were tested with t test, nonparametric test or x2 test. p\<0.05 was regarded as statistically significance.

Eligibility criteria:
inclusion criteria: * participants meeting the following criteria were included in study: 1. had a diagnosis of mt (cycle length irregularity: 7 days earlier or later than usual, the last menstruation was no longer than 11 month earliar over the previous year; specific symptoms of mt: hot flashes, night sweating, insomnia, sexual problems, anxiety, depression etc.); 2. aged from 40 to 55 years old; 3. pregnancy test was negative; 4. participants were informed about the study and signed a consent form voluntarily. exclusion criteria: * participants with any of the following criteria were omitted from the study: 1. 3 month regular cycle length before enrollment; 2. took drugs for treatment in past month like estrogen, soybeans isoflavone, ssris, progestin, black sesame or vitamin e; 3. ovarian and uterine disease: ovarian cyst, uterine myoma more than 4cm in diameter, history of ovariectomy or hysterectomy; 4. willing or plan to become pregnant or to breast-feed; 5. regular took sedatives or anxiolytics; 6. habitual smoker or heavy alcoholic; 7. severe disease: history of radio-chemotherapy, coagulation disorders, severe dysfunction of liver or kidney, application of cardiac pacemaker or artificial joints, insufficiency controlled hypertension, diabetes, thyroid diseases, malignant tumor and psychiatric problems).

Keywords: electro-acupuncture menopause menopausal transition symptoms efficacy rct placebo control
effect of sildenafil in individuals with migraine pretreated with erenumab

Conditions: Migraine Without Aura

Summary: an outstanding scientific question, that merits further investigation, is whether dilation of intracranial arteries is implicated in the pathogenesis of cephalic pain in migraine. here, we hypothesize that experimentally-induced dilation of intracranial arteries using intake of sildenafil (a potent vasodilator) can induce cephalic pain with migraine-like features in people with migraine, who prior to the infusion are administered erenumab (anti-calcitonin gene-related peptide (cgrp) receptor monoclonal antibody.


Eligibility criteria:
inclusion criteria: * participant has provided informed consent prior to initiation of any study-specific activities/procedures. * age ≥18 years upon entry into screening. * history of migraine without aura for ≥12 months with a frequency of 1-5 migraine attacks per month before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018), based on medical records and/or patient self-report. exclusion criteria: * history of any primary headache disorder other than migraine without aura, or tension-type headache with a frequency of ≥5 headache days per month before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018), based on medical records and/or patient self-report. * history of any secondary headache disorder before screening according to the international headache society (ihs) classification ichd-3 (headache classification committee of the international headache society, 2018) based on medical records and/or patient self-report. * intake of prophylactic migraine medication within ≤30 days or 5 plasma half-lives (whichever is longer) prior to screening. * prior intake of therapies targeting the cgrp signaling pathway, including anti-cgrp ligand monoclonal antibodies, anti-cgrp receptor monoclonal antibodies, and small molecule cgrp receptor antagonists. * the participant is at risk of self-harm or harm to others as evidenced by past suicidal behavior. * history or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator will pose a risk to participant safety or interfere with the study evaluation, procedures or completion. * female participants of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a urine pregnancy test. * female participants who are pregnant or breastfeeding or plan to become pregnant or breastfeed during participation in the study. * evidence of current pregnancy or breastfeeding per participant self-report or medical records. * participants likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participants' and investigator's knowledge.
naltrexone for early problem drinkers

Conditions: Alcoholism

Summary: early problem drinkers are prevalent in the united states. recent controlled trials have shown that brief interventions in the primary care setting can reduce drinking and alcohol-related problems in patients who lack evidence of alcohol dependence. although naltrexone (revia) has been approved for the treatment of alcohol dependence, few pharmacotherapy studies have been undertaken with early problem drinkers. this study is an 8-week trial of naltrexone versus placebo, combined with coping skills treatment that either focuses on targeted use of medication or serves as background to daily use of the medication. a total of 160 early problem drinkers recruited through screening in primary care medical settings will be randomly assigned to one of four treatment groups. followup evaluations will be conducted at the end of treatment and again 3, 6, and 12 months.


Eligibility criteria:
inclusion criteria: * limited to early problem drinkers (i.e., those with no more than mild alcohol dependence). * have an average weekly alcohol consumption of greater than or equal to 24 standard drinks for men and 18 standard drinks for women. * able to read english at the eighth grade or higher level and show no evidence of significant cognitive impairment. * willing to provide a collateral informant for interviews regarding the patient's drinking during the study. * a woman of child-bearing potential must be non-lactating, practicing a reliable method of birth control, and have a negative pregnancy test prior to initiation of treatment. * willing to provide a signed informed consent to participate in the study. exclusion criteria: * have a current clinically significant physical disease or abnormality. * have a serious psychiatric illness. * have a current diagnosis of drug dependence (other than nicotine dependence) or a lifetime diagnosis of opioid dependence. * a current diagnosis of alcohol dependence that is moderate or greater in severity or a history of alcohol withdrawal, or recurrent use of alcohol to alleviate alcohol withdrawal symptoms. * used opioids or other psychoactive medications regularly in the month prior to study enrollment. * history of hypersensitivity to naltrexone (revia).
to demonstrate the relative bioavailability of cefzil 500 mg cefprozil tablets under fed conditions

Conditions: Healthy

Summary: the purpose of this study is to demonstrate the relative bioavailability of cefzil 500 mg cefprozil tablets under fed conditions.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.

Keywords: antibiotics
premium trifocal iol comparative analysis

Conditions: Cataract; Lens Opacities; Presbyopia

Summary: short and long-term analysis of the refraction correction and optical image quality of modern premium intraocular lenses (iols) with the establishment of a database for quality assurance and optimization the computation constants of the lens power.

since the investigational lens, like conventional iols, is a posterior chamber lens which is widely implanted following cataract extraction, phacoemulsification is adopted. to assess the binocular vision, the investigational lens will be mono- or bilaterally implanted. clinically retro- and prospective, non-randomized, uncontrolled, open study at several centers: university eye clinic heidelberg (leading center), practice center ahaus in the eye clinic ahaus, breyer, kaymak \& klabe eye surgery in düsseldorf, nordblick eye center kiel. main objectives: 1. functional results (refraction and visual acuity results) secondary goals: 2. deviation target vs. achieved postoperative refraction (for constant optimization of the iol calculation) 3. subjective patient satisfaction 4. visual quality (e.g. scattered light, contrast vision, spherical aberrations) 5. stability of the results achieved postoperatively

Eligibility criteria:
inclusion criteria * availability, willingness and sufficient cognitive awareness to comply with examination procedures * bilateral implantation of one of the following iol models * alcon panoptix (tfnt00) * physiol finevision (pod f) * physiol finevision (pod f gf) * uneventful cataract surgery with first clinical outcomes in the expected range * patient included in premium iol study protocol by signed informed consent exclusion criteria * age of patient \<45 years * irregular astigmatism * postoperative manifested astigmatism of \>1.0 d * difficulty for cooperation (distance from their home, general health condition) * clinically significant glaucoma * clinically significant macular degeneration, clinically significant macular edema or proliferative diabetic retinopathy * patients with keratoconus or keratectasia * any ocular comorbidity having a significant effect on the postoperative clinical outcomes * history of ocular trauma or prior ocular surgery including refractive procedures * capsule or zonular abnormalities that may affect postoperative centration or tilt of the lens (e.g. pseudoexfoliation syndrome, chronic uveitis, marfan's syndrome) * pupil abnormalitis (non-reactive, tonic pupils, abnormally shaped pupils or pupils that do not dilate under mesopic/scotopic conditions) * amd * intraoperative complications like capsular rupture etc. * patients who do not give informed consent

Keywords: intraocular lens trifocal